Search
Oragenics Inc
OGENAdd to Watchlist
0.585USD
-0.004-0.74%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
2.50MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-0.74%
5 Days
-0.36%
1 Month
-2.66%
6 Months
-29.94%
Year to Date
-25.31%
1 Year
-61.76%
Key Figures
0.608Open
0.609High
35.58KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.83%Turnover Ratio
0.606Prev. Close
0.550Low
15.53KTurnover
LossP/E Static
0.30P/B
0.00%Div Yield TTM
-173.03%ROA
9.60052wk High
1.26Volume Ratio
-10.57MNet Profit
4.27MShares
-1.4237EPS TTM
1.27Beta
-311.00%ROE
0.50452wk Low
9.78%Amplitude
100.00%Gross Margin
2.50MMarket Cap
0.18Reward/Risk
4.65%Risk Rate
TradingKey Stock Score of Oragenics Inc
Currency: USD Updated: 2026-07-02Key Insights
Oragenics Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 224 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as , with the highest price target at 2.00.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Oragenics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Oragenics Inc Highlights
StrengthsRisks
Oragenics, Inc. is a development-stage company. It is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. It focuses on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI or Concussion), and for treating Niemann Pick Disease Type C (NPC), and proprietary powder formulation and an intranasal delivery device. Its lead product, ONP-002, is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. It is also focused on developing medical products that treat brain related illnesses and diseases (the Neurology Assets). Its other product candidate, ONP-001, is in its early stage and clinical trials.
Undervalued
The company’s latest PE is -0.41, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 353.35K shares, increasing 30.85% quarter-over-quarter.
Analyst Rating
Based on
0
analysts
--
Current Rating
2.000
Target Price
+229.98%
Upside Space
Oragenics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Oragenics Inc Info
Oragenics, Inc. is a development-stage company. It is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. It focuses on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI or Concussion), and for treating Niemann Pick Disease Type C (NPC), and proprietary powder formulation and an intranasal delivery device. Its lead product, ONP-002, is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. It is also focused on developing medical products that treat brain related illnesses and diseases (the Neurology Assets). Its other product candidate, ONP-001, is in its early stage and clinical trials.
Ticker SymbolOGEN
CompanyOragenics Inc
CEOHuffman (Janet)
Websitehttps://www.oragenics.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Oragenics Inc (OGEN)?
The current price of Oragenics Inc (OGEN) is 0.58.
What is the symbol of Oragenics Inc?
The ticker symbol of Oragenics Inc is OGEN.
What is the 52-week high of Oragenics Inc?
The 52-week high of Oragenics Inc is 9.60.
What is the 52-week low of Oragenics Inc?
The 52-week low of Oragenics Inc is 0.50.
What is the market capitalization of Oragenics Inc?
The market capitalization of Oragenics Inc is 2.50M.
What is the Earnings Per Share (EPS TTM) of Oragenics Inc (OGEN)?
The Earnings Per Share (EPS TTM) of Oragenics Inc (OGEN) is -4.56.